Open Access

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’

  • Norikazu Yamada1Email author,
  • Atsushi Hirayama2,
  • Hideaki Maeda3,
  • Satoru Sakagami4,
  • Hiroo Shikata5,
  • Martin H. Prins6,
  • Anthonie W. A. Lensing7,
  • Masaharu Kato8,
  • Junichi Onuma8,
  • Yuki Miyamoto8,
  • Kazuma Iekushi8 and
  • Mariko Kajikawa8
Thrombosis Journal201614:11

https://doi.org/10.1186/s12959-016-0085-1

Received: 25 April 2016

Accepted: 25 April 2016

Published: 23 May 2016

The original article was published in Thrombosis Journal 2015 13:2

Unfortunately, the original version of this article [1] contained errors. The errors have been addressed point by point in full detail below.

Correction 1

Regarding primary efficacy endpoint (symptomatic recurrent VTE) and composite outcome of symptomatic recurrent VTE or asymptomatic deterioration in rivaroxaban group, we’ve found “1.3 %” (1 patient in 78 population), is correct instead of current “1.4 %”, it should be replaced in Page 1, Line 16 in the abstract section, and on the right side of Page 5, Line 1. However, it is not necessary to replace the number “1.4%” in Table 3 because it was calculated by another definition. Therefore we also would like to add a description of the excluded population, “patients assessed as “not evaluable” were excluded from these analyses”, in footnotes of Table 2 and Table 3.

Correction 2

Due to changes made in correction 1, we need to recalculate absolute risk differences and 95 % Confidence Interval of composite outcome of symptomatic recurrent VTE or asymptomatic deterioration, and we consider these numbers also need to be corrected. And to clarify this “difference” means rivaroxaban reduces risk compared to control, we would like to choose the absolute risk “reduction” instead of “difference”. Absolute risk “reduction” was 4.0 % compared to control, and 95 % CI was (-2.9 to 24.0). We should change these numbers in Page 1, Line 17 in the abstract section, in the right side of Page 5, Line 2 and in the right side of Page 6, Line 6.

Correction 3

There was a trivial miscalculation of percentage in the Table 3. Rivaroxaban combined result in DVT and PE patients, 2 patients in 71 was evaluated as “unchanged”, therefore percentage is “2.8 %” instead of current “2.9 %”.
 

Old text

New text

Abstract

Page 1

Line 15 to 17

The composite of symptomatic venous thromboembolic events or asymptomatic deterioration occurred in 1 (1.4 %) rivaroxaban patient and in 1 (5.3 %) UFH/warfarin patient (absolute risk difference, 3.9 % [95 % confidence interval, -3.4–23.8]).

The composite of symptomatic venous thromboembolic events or asymptomatic deterioration occurred in 1 (1.3 %) rivaroxaban patient and in 1 (5.3 %) UFH/warfarin patient (absolute risk reduction, 4.0 % [95 % confidence interval, -2.9-24.0]).

Method

Right side

Page 3

Line 23 to 25

Crude percentages and absolute differences and their 95 % confidence intervals were calculated.

Crude percentages and absolute reduction and their 95 % confidence intervals were calculated.

Result

Left side

Page 5

Line 2 to 4

A single patient in the rivaroxaban group (1/78; 1.4 %) developed symptomatic recurrent VTE compared with none of the 19 patients allocated to control treatment.

A single patient in the rivaroxaban group (1/78; 1.3 %) developed symptomatic recurrent VTE compared with none of the 19 patients allocated to control treatment.

Result

Left side

Page 5

Line 9 to 12

VTE and asymptomatic deterioration at the end of intended treatment occurred in 1 (1.4 %) rivaroxaban patient and in 1 (5.3 %) control patient, with an absolute risk difference of 3.9 % (95 % confidence interval −3.4 to 23.8).

VTE and asymptomatic deterioration at the end of intended treatment occurred in 1 (1.3 %) rivaroxaban patient and in 1 (5.3 %) control patient, with an absolute risk reduction of 4.0 % (95 % confidence interval −2.9 to 24.0) compared to control.

Result

Right side

Page 5

Line 5 to 8

At day 22, the combined venous ultrasound and lung imaging result in patients with DVT and/or PE showed normalization in 20 (26.7 %) of the 75 rivaroxaban recipients and in 3 (15.8 %) of the 19 control patients.

At day 22, the combined venous ultrasound and lung imaging result in evaluable patients with DVT and/or PE showed normalization in 20 (26.7 %) of the 75 rivaroxaban recipients and in 3 (15.8 %) of the 19 control patients.

Result

Page 5

Table 2

Footnote

bid, twice daily, DVT, deep vein thrombosis; od, once daily; PE, pulmonary embolism; UFH, unfractionated heparin; VTE, venous thromboembolism.

*Symptomatic recurrent VTE during first 22 days.

bid, twice daily, DVT, deep vein thrombosis; od, once daily; PE, pulmonary embolism; UFH, unfractionated heparin; VTE, venous thromboembolism.

Patients assessed as "not evaluable" were excluded from these analyses. *Symptomatic recurrent VTE during first 22 days.

Result

Page 6,

Table 3

Line 21

2 (2.9)

2 (2.8)

Result

Page 6

Table 3

Footnote

bid, twice daily, DVT, deep vein thrombosis; od, once daily; PE, pulmonary embolism; UFH, unfractionated heparin; VTE, venous thromboembolism.

*Symptomatic recurrent VTE during the entire intended treatment period.

bid, twice daily, DVT, deep vein thrombosis; od, once daily; PE, pulmonary embolism; UFH, unfractionated heparin; VTE, venous thromboembolism.

Patients assessed as "not evaluable" were excluded from these analyses. *Symptomatic recurrent VTE during the entire intended treatment period.

Discussion

Page 6

Left side

Line 9 to 12

The lower limit of the confidence interval (i.e. –3.4 %) around the absolute difference in the composite efficacy outcome suggests that an important deterioration in treatment effect can be excluded for rivaroxaban.

The lower limit of the confidence interval (i.e. –2.9 %) around the absolute reduction in the composite efficacy outcome suggests that an important deterioration in treatment effect can be excluded for rivaroxaban.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine
(2)
Division of Cardiology, Department of Medicine, Nihon University School of Medicine
(3)
Division of Cardiovascular, Respiratory and general surgery, Nihon University School of Medicine
(4)
Department of Cardiology, National Hospital Organization, Kanazawa Medical Center
(5)
Department of Cardiovascular Surgery, Kanazawa Medical University
(6)
Maastricht University Medical Center
(7)
Bayer HealthCare Pharmaceuticals
(8)
Bayer Yakuhin Ltd

Reference

  1. Yamada N, Hirayama A, Maeda H, Sakagami S, Shikata H, Prins MH, Lensing A W A, Kato M, Onuma J, Miyamoto Y, Iekushi K and Kajikawa M. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program. Thromb J. 2015;13:2.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Yamada et al. 2016

Advertisement